石药集团：SYH2046片获美国临床试验批准

Core Viewpoint - The company Shiyao Group has received approval from the U.S. FDA to conduct clinical trials for its new drug SYH2046, which is aimed at treating heart failure after acute myocardial infarction [1] Group 1 - SYH2046 is a first-in-class small molecule drug with complete independent intellectual property rights [1] - The drug has also been approved by the National Medical Products Administration of China to conduct clinical trials starting from April 2025 [1] - The specific indication for the clinical trial approved by the FDA is heart failure following acute myocardial infarction [1]